The unconjugated portion of the commercial formulation for tarcocimab contains a high molar equivalent to approved intravitreal biologics Brolucizumab Ranibizumab Aflibercept Faricimab Tarcocimab Old Formulation Tarcocimab Commercial Formulation Molecule Type Single-Chain Antibody Fragment Antibody Fragment Fusion Protein Antibody Antibody Biopolymer Conjugate (ABC) Unconjugated antibody + ABC Molecular Structure Molecular Weight 26 kDa 48 kDa 115 kDa 149 kDa 950 kDa 150 kDa 950 kDa Clinical Dose 6 mg 0.3-0.5 mg 2 mg 6 mg 5 mg By weight of antibody 5 mg 1 mg 4 mg Equivalent Molar Dose 11 0.5 1.0 2 3.5 0.7 2.8 Equivalent values are shown as fold changes relative to aflibercept. kDa = kilodalton Equivalent to 2 mg of faricimab 1.3 mg of aflibercept 0.7 mg of ranibizumab 25